Natixis
- SEC CIK
- 0001274981
- Latest filing
- Aug 13, 2026
TXG holding history
10x Genomics, Inc. in every 13F filed by Natixis, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
TXG overviewAll 13F holders of TXGFull Q2 2026 holdings
- Shares (Q3 2025)
- 0
- Sold out in Q3 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 7
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q3 2025 | 0 | $0 | 0.0% | −300−100.0% | Sold out | Holders |
| Q2 2025 | 300 | $3.47K | <0.1% | +300 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −1,915−100.0% | Sold out | Holders |
| Q1 2023 | 1,915 | $106.8K | <0.1% | −120−5.9% | Reduced | Holders |
| Q4 2022 | 2,035 | $74.2K | <0.1% | +2,035 | New | Holders |
| Q2 2022 | 0 | $0 | 0.0% | −26,537−100.0% | Sold out | Holders |
| Q1 2022 | 26,537 | $2.02M | <0.1% | −26,013−49.5% | Reduced | Holders |
| Q4 2021 | 52,550 | $7.83M | <0.1% | +11,158+27.0% | Added | Holders |
| Q3 2021 | 41,392 | $6.03M | <0.1% | +41,392 | New | Holders |
| Q2 2021 | 0 | $0 | 0.0% | −46,152−100.0% | Sold out | Holders |
| Q1 2021 | 46,152 | $8.35M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.